Table 2

Median expression levels of the six selected miRNAs and associations with clinicopathological data
Number (percent) miR-21 miR-31 miR-92a miR-101 miR-106a miR-145
Gender
 Female 81 (42) 7.78 0.07 1.64 0.02 1.16 0.43
 Male 112 (58) 7.53 0.03 2.12 0.02 0.93 0.48
p-value 0.45 0.14 0.52 0.78 0.43 0.99
TNM
 I 35 (18) 5.22 0.02 2.41 0.02 1.24 0.34
 II 97 (50) 7.67 0.06 2.09 0.02 1.10 0.48
 III 61 (32) 7.78 0.07 1.59 0.02 0.85 0.51
p-value 0.23 0.02 0.80 0.86 0.54 0.30
pT
 1 4 (2) 7.90 0.02 2.51 0.02 1.16 0.36
 2 36 (19) 5.15 0.02 2.45 0.02 1.26 0.36
 3 133 (69) 7.67 0.05 1.74 0.02 0.88 0.46
 4 20 (10) 8.50 0.14 2.58 0.02 1.33 0.58
p-value 0.37 0.004 0.61 0.76 0.52 0.70
pN
 0 132 (68) 7.53 0.04 2.12 0.02 1.15 0.44
 1 39 (20) 7.67 0.05 1.73 0.02 0.89 0.46
 2 22 (11) 8.47 0.09 1.39 0.02 0.82 0.59
p-value 0.82 0.31 0.60 0.95 0.54 0.63
Differentiation
 Well 6 (3) 3.58 0.02 1.09 0.01 0.38 0.24
 Intermediate 167 (87) 7.67 0.04 2.14 0.02 1.16 0.45
 Poor 20 (10) 6.83 0.20 0.95 0.02 0.70 0.69
p-value 0.28 0.001 0.003 0.33 0.01 0.12
Tumor localization
 Colon 129 (67) 7.52 0.07 1.62 0.02 0.87 0.43
 Rectum 64 (33) 7.77 0.02 2.58 0.02 1.27 0.67
p-value 0.50 0.02 0.05 0.32 0.05 0.08
Lymphocyte infiltration
 High 26 (14) 7.93 0.09 1.96 0.02 0.88 0.63
 Intermediate 125 (65) 7.78 0.03 2.14 0.02 1.01 0.51
 Low 40 (21) 6.91 0.08 1.46 0.02 1.04 0.33
p-value 0.47 0.19 0.49 0.82 0.37 0.14
Vascular invasion
 Present 38 (20) 7.73 0.07 1.54 0.02 1.17 0.59
 Absent 155 (80) 7.36 0.04 2.01 0.02 0.98 0.43
p-value 0.30 0.23 0.43 0.27 0.94 0.05
Perineural invasion
 Present 16 (8) 8.60 0.16 1.68 0.02 1.05 0.35
 Absent 177 (92) 7.54 0.04 1.95 0.02 0.98 0.48
p-value 0.42 0.43 0.60 0.29 0.83 0.49
Perinodal growth*
 Present 38 (62) 8.09 0.11 1.46 0.02 0.81 0.52
 Absent 23 (38) 7.36 0.03 2.01 0.02 1.10 0.36
p-value 0.77 0.36 0.30 1.00 0.18 0.49

*Associations between miRNA expression and clinicopathological variables were explored using Mann–Whitney or Kruskal-Wallis test as appropriate; p-values are given in italic. Total number of patients included in the analyses was 193, median age was 73 years.

** Perinodal growth was only assessed in the lymph node positive patients.

Schee et al.

Schee et al. BMC Cancer 2012 12:505   doi:10.1186/1471-2407-12-505

Open Data